| pubmed-article:11206041 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:11206041 | lifeskim:mentions | umls-concept:C0683141 | lld:lifeskim |
| pubmed-article:11206041 | lifeskim:mentions | umls-concept:C0005516 | lld:lifeskim |
| pubmed-article:11206041 | lifeskim:mentions | umls-concept:C0035064 | lld:lifeskim |
| pubmed-article:11206041 | lifeskim:mentions | umls-concept:C1522240 | lld:lifeskim |
| pubmed-article:11206041 | lifeskim:mentions | umls-concept:C1519941 | lld:lifeskim |
| pubmed-article:11206041 | lifeskim:mentions | umls-concept:C1516048 | lld:lifeskim |
| pubmed-article:11206041 | lifeskim:mentions | umls-concept:C0936012 | lld:lifeskim |
| pubmed-article:11206041 | lifeskim:mentions | umls-concept:C0205549 | lld:lifeskim |
| pubmed-article:11206041 | lifeskim:mentions | umls-concept:C0205198 | lld:lifeskim |
| pubmed-article:11206041 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:11206041 | pubmed:dateCreated | 2001-2-1 | lld:pubmed |
| pubmed-article:11206041 | pubmed:abstractText | Renal drug elimination is determined by glomerular filtration, tubular secretion, and tubular reabsorption. Changes in the integrity of these processes influence renal drug clearance, and these changes may not be detected by conventional measures of renal function such as creatinine clearance. The aim of the current study was to examine the analytic issues needed to develop a cocktail of marker drugs (fluconazole, rac-pindolol, para-aminohippuric acid, sinistrin) to measure simultaneously the mechanisms contributing to renal clearance. High-performance liquid chromatographic methods of analysis for fluconazole, pindolol, para-aminohippuric acid, and creatinine and an enzymatic assay for sinistrin were developed or modified and then validated to allow determination of each of the compounds in both plasma and urine in the presence of all other marker drugs. A pilot clinical study in one volunteer was conducted to ensure that the assays were suitable for quantitating all the marker drugs to the sensitivity and specificity needed to allow accurate determination of individual renal clearances. The performance of all assays (plasma and urine) complied with published validation criteria. All standard curves displayed linearity over the concentration ranges required, with coefficients of correlation greater than 0.99. The precision of the interday and intraday variabilities of quality controls for each marker in plasma and urine were all less than 11.9% for each marker. Recoveries of markers (and internal standards) in plasma and urine were all at least 90%. All markers investigated were shown to be stable when plasma or urine was frozen and thawed. For all the assays developed, there were no interferences from other markers or endogenous substances. In a pilot clinical study, concentrations of all markers could be accurately and reproducibly determined for a sufficient duration of time after administration to calculate accurate renal clearance for each marker. This article presents details of the analytic techniques developed for measuring concentrations of marker drugs for different renal elimination processes administered as a single dose to define the processes contributing to renal drug elimination. | lld:pubmed |
| pubmed-article:11206041 | pubmed:language | eng | lld:pubmed |
| pubmed-article:11206041 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11206041 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:11206041 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11206041 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11206041 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11206041 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11206041 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11206041 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11206041 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11206041 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11206041 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11206041 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:11206041 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:11206041 | pubmed:month | Feb | lld:pubmed |
| pubmed-article:11206041 | pubmed:issn | 0163-4356 | lld:pubmed |
| pubmed-article:11206041 | pubmed:author | pubmed-author:BealJ LJL | lld:pubmed |
| pubmed-article:11206041 | pubmed:author | pubmed-author:GrossA SAS | lld:pubmed |
| pubmed-article:11206041 | pubmed:author | pubmed-author:TettS ESE | lld:pubmed |
| pubmed-article:11206041 | pubmed:author | pubmed-author:McLachlanA... | lld:pubmed |
| pubmed-article:11206041 | pubmed:author | pubmed-author:MinneWW | lld:pubmed |
| pubmed-article:11206041 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:11206041 | pubmed:volume | 23 | lld:pubmed |
| pubmed-article:11206041 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:11206041 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:11206041 | pubmed:pagination | 39-46 | lld:pubmed |
| pubmed-article:11206041 | pubmed:dateRevised | 2006-11-15 | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:meshHeading | pubmed-meshheading:11206041... | lld:pubmed |
| pubmed-article:11206041 | pubmed:year | 2001 | lld:pubmed |
| pubmed-article:11206041 | pubmed:articleTitle | Analytical validation for a series of marker compounds used to assess renal drug elimination processes. | lld:pubmed |
| pubmed-article:11206041 | pubmed:affiliation | Faculty of Pharmacy, The University of Sydney, St. Leonards, New South Wales, Australia. | lld:pubmed |
| pubmed-article:11206041 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:11206041 | pubmed:publicationType | Clinical Trial | lld:pubmed |
| pubmed-article:11206041 | pubmed:publicationType | Research Support, Non-U.S. Gov't | lld:pubmed |
| pubmed-article:11206041 | pubmed:publicationType | Validation Studies | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11206041 | lld:pubmed |
| http://linkedlifedata.com/r... | pubmed:referesTo | pubmed-article:11206041 | lld:pubmed |
